Vanguard Group Inc Longboard Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,925,147 shares of LBPH stock, worth $65.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,925,147

Previous 1,724,431 11.64%

Holding current value

$65.1 Million

Previous $37.2 Million 39.71%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$17.0 - $27.03 $3.41 Million - $5.43 Million	200,716 Added 11.64%	1,925,147 $52 Million
Q1 2024 May 10, 2024	BUY	$18.89 - $26.06 $17.7 Million - $24.4 Million	937,998 Added 119.27%	1,724,431 $37.2 Million
Q4 2023 Feb 14, 2024	BUY	$3.68 - $6.5 $19,724 - $34,840	5,360 Added 0.69%	786,433 $4.74 Million
Q3 2023 Nov 14, 2023	BUY	$5.49 - $7.49 $625,168 - $852,916	113,874 Added 17.07%	781,073 $4.34 Million
Q2 2023 Aug 14, 2023	BUY	$4.19 - $10.05 $1.13 Million - $2.7 Million	268,720 Added 67.44%	667,199 $4.9 Million
Q1 2023 May 15, 2023	BUY	$3.84 - $5.96 $352,880 - $547,700	91,896 Added 29.97%	398,479 $1.6 Million
Q4 2022 Feb 10, 2023	BUY	$2.95 - $5.5 $11,313 - $21,092	3,835 Added 1.27%	306,583 $999,000
Q3 2022 Nov 14, 2022	SELL	$2.95 - $4.7 $2,952 - $4,704	-1,001 Reduced 0.33%	302,748 $1.13 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $9.45 $619,400 - $1.23 Million	130,400 Added 75.22%	303,749 $1.48 Million
Q3 2021 Nov 12, 2021	BUY	$8.65 - $11.36 $67,504 - $88,653	7,804 Added 4.71%	173,349 $1.53 Million
Q2 2021 Aug 13, 2021	BUY	$7.95 - $17.3 $1.32 Million - $2.86 Million	165,545 New	165,545 $1.51 Million

Others Institutions Holding LBPH

# of Institutions

101

Shares Held

34.1M

Call Options Held

8.5K

Put Options Held

31.1K

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $460M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Longboard Pharmaceuticals, Inc. Transaction History